Concordia Names Six Drugs Targeted By UK Competition Inquiry

Concordia has announced that six more of its medicines are involved in the UK competition inquiry. One law firm says the announcement further underlines the Competition and Markets Authority’s determination to root out anticompetitive practices in the pharma area.

Hurdles
The CMA is continuing its pursuit of unfair competition

Concordia International Corp. has revealed the names of six of its products that are the subject of additional investigations opened in October last year by the UK Competition and Markets Authority as part of the CMA’s ongoing probe into anticompetitive behavior in the pharmaceutical market.

The products are: the hyperthyroidism drug carbimazole, the muscle relaxant dicycloverine, the analgesic nefopam, the antibiotic nitrofurantoin, prochlorperazine for schizophrenia,...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet